MedTrace Logo

Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women

NCT03408262 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-10-16

Study results available
· View outcomes & findings →

Summary

A Phase I Single-Blind randomised trial investigating immunisation strategies using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA combinations in order to maximise antibody responses to Human Immunodeficiency Virus

Conditions

  • Human Immunodeficiency Virus

Interventions

BIOLOGICAL

Ad4-EnvCN54

Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

BIOLOGICAL

MVA-CN54

Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

BIOLOGICAL

CN54gp140/MPLA

Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • David Lewis, MD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-06
Primary Completion
2020-02-10
Completion
2020-02-10
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03408262 on ClinicalTrials.gov